Adoptive immunotherapy poised to deliver on decades-old promise.
Karyn
K
Hede
D002986:Clinical Trials as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000191:economics* / Q000379:methods*; D007348:Insurance, Health; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000276:immunology; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D019057:Quality-Adjusted Life Years; D012074:Remission Induction; D012109:Research Support as Topic; D013601:T-Lymphocytes / Q000276:immunology*